Chidamide with Rituximab for Relapsed/Refratory Germinal Center subtype of Diffuse Large B Cell Lymphoma

Trial Profile

Chidamide with Rituximab for Relapsed/Refratory Germinal Center subtype of Diffuse Large B Cell Lymphoma

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 01 Jul 2016

At a glance

  • Drugs Rituximab (Primary) ; Tucidinostat (Primary)
  • Indications B cell lymphoma
  • Focus Biomarker; Pharmacodynamics; Therapeutic Use
  • Most Recent Events

    • 01 Jul 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top